Logo

Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

Share this
Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

Shots:
  • The approval is based on results of ongoing P-III CONVERT study conducted at 18 countries with 125 sites assessing Arikayce + guideline-based therapy (GBT) vs GBT alone with refractory nontuberculous mycobacterial (NTM) lung disease caused by MAC
  • P-III CONVERT study Results: ARIKAYCE+GBT reduced evidence of NTM lung disease caused by MAC in sputum @6 mos. (29% vs 9%)- showing its safety and efficacy
  • ARIKAYCE is a novel therapy approved in the US for patients with MAC lung disease an also first product approved via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
/ article | Ref: Insmed | Image: Insmed

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions